IL164195A0 - Parenteral, intravenous, and oral administration of oxazolidinones for treating diabetic foot infections - Google Patents

Parenteral, intravenous, and oral administration of oxazolidinones for treating diabetic foot infections

Info

Publication number
IL164195A0
IL164195A0 IL16419503A IL16419503A IL164195A0 IL 164195 A0 IL164195 A0 IL 164195A0 IL 16419503 A IL16419503 A IL 16419503A IL 16419503 A IL16419503 A IL 16419503A IL 164195 A0 IL164195 A0 IL 164195A0
Authority
IL
Israel
Prior art keywords
oxazolidinones
parenteral
intravenous
oral administration
diabetic foot
Prior art date
Application number
IL16419503A
Other languages
English (en)
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of IL164195A0 publication Critical patent/IL164195A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18Oxygen atoms
    • C07D263/20Oxygen atoms attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/4211,3-Oxazoles, e.g. pemoline, trimethadione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL16419503A 2002-03-29 2003-03-21 Parenteral, intravenous, and oral administration of oxazolidinones for treating diabetic foot infections IL164195A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36910402P 2002-03-29 2002-03-29
PCT/US2003/008882 WO2003084534A1 (en) 2002-03-29 2003-03-21 Parenteral, intravenous, and oral administration of oxazolidinones for treating diabetic foot infections

Publications (1)

Publication Number Publication Date
IL164195A0 true IL164195A0 (en) 2005-12-18

Family

ID=28791924

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16419503A IL164195A0 (en) 2002-03-29 2003-03-21 Parenteral, intravenous, and oral administration of oxazolidinones for treating diabetic foot infections

Country Status (16)

Country Link
US (1) US20030216330A1 (xx)
EP (1) EP1490059A1 (xx)
JP (1) JP2005527575A (xx)
KR (1) KR20040095328A (xx)
CN (1) CN1642543A (xx)
AU (1) AU2003223334A1 (xx)
BR (1) BR0308806A (xx)
CA (1) CA2476545A1 (xx)
IL (1) IL164195A0 (xx)
MX (1) MXPA04009356A (xx)
NO (1) NO20044672L (xx)
NZ (1) NZ535648A (xx)
PL (1) PL372661A1 (xx)
RU (1) RU2354372C2 (xx)
WO (1) WO2003084534A1 (xx)
ZA (1) ZA200407734B (xx)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200404069A (en) * 2002-06-28 2004-03-16 Upjohn Co Difluorothioacetamides of oxazolidinones with a glycoloylpiperazine substituent
JP4579502B2 (ja) * 2003-05-02 2010-11-10 キヤノン株式会社 構造体及びその製造方法、該構造体を含むトナー並びにそれを用いた画像形成方法及び装置
AR045690A1 (es) 2003-06-03 2005-11-09 Rib X Pharmaceuticals Inc Compuestos biaril heterociclicos y metodos para preparar y utilizar los mismos
US8324398B2 (en) 2003-06-03 2012-12-04 Rib-X Pharmaceuticals, Inc. Process for the synthesis of biaryl oxazolidinones
WO2005061468A1 (en) * 2003-12-17 2005-07-07 Rib-X Pharmaceuticals, Inc. Halogenated biaryl heterocyclic compounds and methods of making and using the same
WO2006008640A1 (en) * 2004-07-15 2006-01-26 Pharmacia & Upjohn Company Llc Non-aqueous suspension containing a drug having an unpleasant taste
TW200612923A (en) * 2004-07-29 2006-05-01 Ferrer Int Oxazolidinone compounds and compositions and methods related thereto
US8399660B2 (en) 2005-06-08 2013-03-19 Rib-X Pharmaceuticals, Inc. Process for the synthesis of triazoles
ES2335307T3 (es) 2005-06-29 2010-03-24 PHARMACIA & UPJOHN COMPANY LLC Homomorfolin oxalidinonas como agentes antibacterianos.
US9427468B2 (en) * 2007-08-22 2016-08-30 Trustees Of Dartmouth College Compositions and methods for diagnosing and treating community-acquired methicillin-resistant Staphylococcus aureus
UY32493A (es) * 2009-03-16 2010-10-29 Astrazeneca Ab " (5r)-3-[4-[1-[(2s)-2,3-dihidroxipropanoil]-3,6-dihidro-2h-piridin-4-il]-3,5-difluorofenil]-5-(isoxazol-3-iloximetil)oxazolidin-2-ona, sus sales farmacéuticamente aceptables, sus ésteres hidrolizables y aplicaciones"
US9795601B2 (en) * 2010-12-15 2017-10-24 Biovista, Inc. Compositions and methods for cancer treatment

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4705799A (en) * 1983-06-07 1987-11-10 E. I. Du Pont De Nemours And Company Aminomethyl oxooxazolidinyl benzenes useful as antibacterial agents
US5254577A (en) * 1988-07-29 1993-10-19 The Du Pont Merck Pharmaceutical Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
US5043443A (en) * 1988-07-29 1991-08-27 Du Pont Merck Pharmaceutical Company Aminomethyloxooxazolidinyl arylbenzene derivatives
US5225565A (en) * 1988-09-15 1993-07-06 The Upjohn Company Antibacterial 3-(fused-ring substituted)phenyl-5β-amidomethyloxazolidin-2-ones
US5164510A (en) * 1988-09-15 1992-11-17 The Upjohn Company 5'Indolinyl-5β-amidomethyloxazolidin-2-ones
US5182403A (en) * 1988-09-15 1993-01-26 The Upjohn Company Substituted 3(5'indazolyl) oxazolidin-2-ones
US5231188A (en) * 1989-11-17 1993-07-27 The Upjohn Company Tricyclic [6.5.51]-fused oxazolidinone antibacterial agents
EP0610265B1 (en) * 1991-11-01 1996-12-27 PHARMACIA & UPJOHN COMPANY Substituted aryl- and heteroarylphenyloxazolidinones useful as antibacterial agents
SK283420B6 (sk) * 1992-05-08 2003-07-01 Pharmacia & Upjohn Company Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny
DK0673370T3 (da) * 1992-12-08 1998-09-07 Upjohn Co Troponsubstituerede phenyloxazolidinoner som antibakterielle midler
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
CN1046276C (zh) * 1993-11-22 1999-11-10 法玛西雅厄普约翰美国公司 取代羟基乙酰基哌嗪苯基唑烷酮酯及其用途
DE4425609A1 (de) * 1994-07-20 1996-01-25 Bayer Ag Benzofuranyl- und Benzothienyloxazolidinone
DE4425613A1 (de) * 1994-07-20 1996-01-25 Bayer Ag 5-gliedrige Heteroaryl-oxazolidinone
DE4425612A1 (de) * 1994-07-20 1996-04-04 Bayer Ag 6-gliedrige stickstoffhaltige Heteroaryl-oxazolidinone
DE19514313A1 (de) * 1994-08-03 1996-02-08 Bayer Ag Benzoxazolyl- und Benzothiazolyloxazolidinone
ATE233766T1 (de) * 1994-11-15 2003-03-15 Upjohn Co Antibakterielle bizyklische oxazin und thiazin- oxazolidinone
HRP960159A2 (en) * 1995-04-21 1997-08-31 Bayer Ag Benzocyclopentane oxazolidinones containing heteroatoms
ATE207487T1 (de) * 1995-09-01 2001-11-15 Upjohn Co Phenyloxazolidinone mit einer c-c-bindung zu 4-8 gliedrigen heterocyclen
DE19601264A1 (de) * 1996-01-16 1997-07-17 Bayer Ag Pyrido-annellierte Thienyl- und Furanyl-Oxazolidinone
DE19604223A1 (de) * 1996-02-06 1997-08-07 Bayer Ag Neue substituierte Oxazolidinone
WO1999037630A1 (en) * 1998-01-23 1999-07-29 Versicor, Inc. Oxazolidinone combinatorial libraries, compositions and methods of preparation
MY122454A (en) * 1998-06-05 2006-04-29 Upjohn Co Use of oxazolidinones for the preparation of a medicament for transdermal delivery
ATE301474T1 (de) * 2000-06-30 2005-08-15 Pharmacia & Upjohn Co Llc Zusammensetzungen zur behandlung baktrieller infektionen, welche ein oxazolidinonderivat, sulbactam und ampicillin enthalten

Also Published As

Publication number Publication date
RU2004131830A (ru) 2005-04-10
US20030216330A1 (en) 2003-11-20
WO2003084534A1 (en) 2003-10-16
KR20040095328A (ko) 2004-11-12
CN1642543A (zh) 2005-07-20
NZ535648A (en) 2007-05-31
JP2005527575A (ja) 2005-09-15
MXPA04009356A (es) 2005-01-25
PL372661A1 (en) 2005-07-25
CA2476545A1 (en) 2003-10-16
AU2003223334A1 (en) 2003-10-20
ZA200407734B (en) 2005-06-24
NO20044672L (no) 2004-12-23
BR0308806A (pt) 2005-01-04
EP1490059A1 (en) 2004-12-29
RU2354372C2 (ru) 2009-05-10

Similar Documents

Publication Publication Date Title
TW200505881A (en) Tri(cyclo) substituted amide compounds
NO20053224D0 (no) Patient controlled drug administration device.
HK1087337A1 (en) Use of a hif-alpha stabilizing agent for the preparation of medicament for treatment of diabetes
WO2004032909A3 (en) Stabilized pharmaceutical composition containing basic excipients
IL164195A0 (en) Parenteral, intravenous, and oral administration of oxazolidinones for treating diabetic foot infections
HK1085667A1 (en) Non-nucleoside reverse transcriptase inhibitors
IN2015DN01132A (xx)
IL239913A0 (en) The use of delvavancin in a pharmaceutical carrier is accepted in the production of a drug for the treatment of bacterial infections
WO2005058233A3 (en) Methods for treatment of acute pancreatitis
TW200806295A (en) Long term treatment of HIV infection
AU2003279253A1 (en) Silicone blends and composites for drug delivery
NO20013958L (no) Legemiddel for behandling av höyt blodtrykk
AU2003252182A8 (en) Therapeutic treatment for the metabolic syndrome and type 2 diabetes
IT1308678B1 (it) Siringa per infusione di farmaci.
IL158794A0 (en) The use of adenosine and analogues for producing medicines for the treatment of the insulin resistance syndrome and diabetes
EP1684783A4 (en) NEUROPROTECTIVE EFFECTS OF GLY-PRO-GLU AFTER INTRAVENOUS INFUSION
GB0212790D0 (en) Medicament for the treatment of diabetes
EP1526838B8 (de) Intravenös applizierbare, pharmazeutische darreichungsform
GB0327493D0 (en) Treatment medicament
AU2003285125A8 (en) Polymer compositions comprising antifibrotic agents, and methods of treatment, pharmaceutical compositions, and methods of preparation therefor
PL362702A1 (en) Pharmaceutical composition for the treatment of diabetes comprising a 5-phenoxyalkal-2,4-thiazolidinedione derivative and a compound that stimulates insulin secretion
EG23366A (en) Oral film containing chlorhexidine hydrochloride and benzydamine hydrochloride for treatment of gingivitis, peridontitis and oral infections.
ITCT20020009V0 (it) Deflussore autobloccante per infusione endovenosa anti-embolia.
RU2004105675A (ru) Способ комплексного лечения язв роговицы
AU2002953242A0 (en) Veterinary intravenous administration apparatus